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The spike (S) and hemagglutinin/esterase (HE) of bovine coronavirus (BCV) are the two envelope proteins that recognize
the same receptor-determinant of 9-O-acetylneuraminic acid on host cells. However, the precise and relative roles of the two
proteins in BCV infectivity remain elusive. To unequivocally determine their roles in viral cytopathogenicity, we developed a
system in which phenotypically chimeric viruses were generated by infecting a closely related mouse hepatitis virus (MHV)
in cells that stably express an individual BCV protein (S or HE). The chimeric viruses were then used to infect human rectal
tumor (HRT)-18 cells that are permissive to BCV but are nonsusceptible to MHV. Using this approach, we found that the
chimeric virus containing the BCV S protein on the virion surface entered and replicated in HRT-18 cells; this was specifically
blocked by prior treatment of the virus with a neutralizing antibody specific to the BCV S protein, indicating that the BCV S
protein is responsible for initiating chimeric virus infection. In contrast, chimeric viruses that contain biologically active and
functional BCV HE protein on the surface failed to enter HRT-18 cells, indicating that the BCV HE protein alone is not sufficient
for BCV infection. Taken together, these results demonstrate that the S protein but not the HE protein of BCV is necessaryINTRODUCTION
Coronaviruses are a group of enveloped RNA viruses
that contain a positive-sense, single-strand RNA genome
of 27–31 kb in length (Lai and Cavanagh, 1997). A typical
coronaviral particle is round, ranging from 120 to 160 nm
in diameter. The large peplomer that protrudes from the
virion envelope forms the typical 20-nm spikes (Lai and
Cavanagh, 1997). In some coronaviruses, a small
peplomer composed of a hemagglutinin/esterase (HE)
protein is also present on the virion surface (King et al.,
1985). Two additional proteins, the membrane glycopro-
tein (M) of 23–26 kDa (Armstrong et al., 1984) and the
small envelope protein (E) of 9–12 kDa (Yu et al., 1994),
are embedded in the envelope and are essential for
virion envelopment, a required process during virion as-
sembly (Rottier et al., 1984; Vennema et al., 1996). The
nucleocapsid (N) protein of 50 kDa is associated with
the RNA genome to form the nucleocapsid inside the
viral envelope (Stohlman and Lai, 1979; Sturman et al.,
1980).
The spike (S) protein of coronavirus, as exemplified by
bovine coronavirus (BCV), contains 1363 amino acids
(aa) with an estimated molecular mass of 151 kDa (Abra-
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All rights reserved.ham et al., 1990; Boireau et al., 1990; Parker et al., 1990;
Zhang et al., 1991b). With its 19 potential glycosylation
sites, the S protein has a size of 190 kDa when fully
glycosylated (Abraham et al., 1990; Cavanagh, 1995).
BCV S protein consists of two subunits: the N-terminal S1
(110 kDa) and the C-terminal S2 (100 kDa) (St. Cyr-Coats
and Storz, 1988). The S1, which forms the bulb portion of
the spike, contains domains responsible for viral attach-
ment to the receptor of host cells, while the S2, which
forms the stem anchoring the spike into the envelope,
possesses regions essential for fusion between viral and
cell membranes during infection (Storz et al., 1992; Yoo et
al., 1991). Cleavage of the S protein into S1 and S2
subunits is mediated by cellular trypsin-like proteases
and is believed an important process in viral infectivity
(Storz et al., 1981). In most coronaviruses, the S protein is
the major and, probably, the only viral structural protein
required for virus entry. For example, it has been shown
that the S protein of transmissible gastroenteritis virus
determines virus infectivity and tissue tropism (Sanchez
et al., 1999). In mouse hepatitis virus (MHV), some strains
(such as JHM) contain the HE protein, while others (such
as A59) do not (Shieh et al., 1989; Yokomori et al., 1989).
Treatment of permissive cells with monoclonal antibody
(mAb) specific to the MHV receptor molecules, which
prevented the S protein from interacting with the recep-
tor, also blocked JHM virus infection (Gagneten et al.,
1995); antibodies specific to the S protein neutralizedand sufficient for infection of the chimeric viruses in HRT-18
vehicle to infect permissive cells. © 2002 Elsevier Science (USA
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(Yokomori et al., 1991). These findings indicate that the S
but not the HE protein of MHV is responsible for viral
infectivity.
In BCV, the HE protein contains 424 aa with an esti-
mated molecular weight of 62 to 65 kDa. It usually exists
in the virion as homodimers of 126 kDa linked by disul-
fate bonds (King et al., 1985). It is evolutionarily closely
related to the HEF protein of influenza C virus (Herrler et
al., 1985, 1988; Luytjes et al., 1988). Like the HEF protein
of influenza C virus (Herrler et al., 1985, 1988; Herrler and
Klenk, 1991), the BCV HE protein also contains receptor-
binding and receptor-destroying activities, although it
lacks fusion activity (Schultze et al., 1990, 1991; Vlasak et
al., 1988). The receptor-destroying activity is associated
with the acetylesterase that hydrolyzes an ester linkage
to release the acetyl group from position C-9 of the
N-acetyl-9-O-acetylneuraminic acid-containing receptors
on host cells and erythrocytes (Vlasak et al., 1988;
Yokomori et al., 1989). The 9-O-acetyl residue is crucial
for influenza C virus recognition of the glycoprotein re-
ceptor, a major determinant for virus attachment and
infection. By analogy to the HEF protein of influenza C
virus, it was hypothesized that the HE protein of BCV is
probably involved in virus attachment to the receptors of
host cells, in addition to the S protein, and facilitates
virus spread. This is in stark contrast to the MHV HE
protein, which lacks the receptor-binding (hemagglutina-
tion) activity (Yokomori et al., 1989). Several lines of
evidence support an important role of the HE protein in
BCV infectivity: (i) The HE protein of BCV was shown to
induce mAbs that neutralized virus infectivity in vitro (in
cell cultures) and in vivo (in animals); four neutralizing
epitopes were identified on the HE protein of BCV (De-
regt and Babiuk, 1987; Deregt et al., 1989). (ii) Treatment
of BCV with inhibitors that specifically inactivate acet-
ylesterase reduced viral infectivity by 3 logs or greater,
while the same treatment of influenza A virus did not
affect virus infectivity, indicating that acetylesterase ac-
tivity is required for BCV infectivity (Vlasak et al., 1988).
(iii) Both the S and HE proteins of BCV recognized the
same receptor-determinant of the cultured cells and
erythrocyte (Schultze et al., 1991; Schultze and Herrler,
1992, 1994). Removal of the N-acetyl-9-O-acetylneura-
minic acid from cultured cells by treatment with neur-
aminidase or acetylesterase rendered the cells resistant
to BCV infection (Schultze and Herrler, 1992). Taken to-
gether, these findings strongly support the hypothesis
that, as opposed to MHV, both the S and HE proteins of
BCV are necessary for virus infection but that either
protein alone is not sufficient for initiating infection.
To test this hypothesis, we developed a system that
allowed us to make pseudotyped chimeric MHV contain-
ing either the S protein or the HE protein of BCV and to
determine the infectivity of these chimeras in human
rectal tumor (HRT-18) cells that are permissive to BCV
infection but are nonsusceptible to MHV infection. Using
this approach, we found that the chimeric MHV contain-
ing the BCV S protein entered and replicated in HRT-18
cells, whereas those containing the BCV HE protein did
not. Our results clearly demonstrate that the S protein but
not the HE protein of BCV is necessary and sufficient for
virus infection in cultured cells.
RESULTS
Establishment of cell lines that stably express the
BCV S protein
In a preliminary study, we attempted to express the
BCV S protein using the MHV defective-interfering (DI)
RNA system that has been successfully used for ex-
pressing several viral and cellular proteins, including the
MHV HE protein, interferon-, and chloramphenicol
acetyltransferase (Liao and Lai, 1994; Liao et al., 1995;
Zhang et al., 1994, 1997, 1998). However, the expression
of the BCV S protein was extremely low using this sys-
tem, as determined by both the fluorescence intensity
and the number of fluorescence cells with flow cytometry
(data not shown). Chimeric MHV containing the BCV S
protein generated by this system failed to infect BCV-
susceptible cells. We assumed that such failure was
likely attributed by two major factors: limitation of the
capacity of the DI RNA system in efficiently expressing
large genes (longer than 4 kb) and the low efficiency of
RNA transfection. To overcome such limitations we ex-
plored the possibility of stably expressing the BCV S
protein in cells via eukaryotic expression vector pcDNA3.
Therefore, we cloned the complete S gene of BCV viru-
lent strain LY-138 into the pcDNA3 vector under the
control of a cytomegalovirus (CMV) immediate early
gene promoter (Fig. 1A). Because this vector also con-
tains a neomycin resistance gene, stably transfected
cells can be selected with the drug geneticin (G418).
Initially, we obtained 50 DBT cell clones that were resis-
tant to G418 treatment for 3–5 weeks. To identify cells
that were expressing the BCV S protein from these drug-
resistant clones, mAb 43C2 specific to the BCV S protein
was used in an immunofluorescence (IF) assay. The IF
assay was the method of choice because mAb 43C2 only
reacts with conformational epitope and does not react
with the S protein in immunoprecipitation or Western blot
assay when the S protein is denatured. We grouped
these clones based on the intensity of fluorescence as
directly compared with that in DBT/V cells (Fig. 1B, a) that
were stably transfected with the vector alone as a neg-
ative control. Out of the 50 cell clones, 7 exhibited a low
level of fluorescence, 27 a medium level, 11 a high level,
and 5 the highest level. Figure 1B shows 2 representative
cell clones that exhibited the highest level of expression
of the BCV S protein (c and e). Within the same clone, all
cells expressed the BCV S protein, as evidenced by
comparison of the fluorescence images with bright field
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images (compare c with d and e with f in Fig. 1B).
However, the expression level varied slightly from cell to
cell depending on the shape and size of the cells at the
time of fixation (Fig. 1B, c and e). Furthermore, the BCV S
protein was expressed predominantly, if not exclusively,
in the cytoplasm. Cytoplasmic localization became more
pronounced when a higher magnification of the micro-
scope lens was used (data not shown). Interestingly,
while in some cells the S protein distributed relatively
evenly throughout the cytoplasm, it concentrated more in
certain compartments (such as Golgi) in other cells (Fig.
1B). The exact reasons for these variations are unknown,
but it is likely that these cells were in different phases of
the cell cycle, since the cell cultures were not synchro-
nized for these experiments. Because the expression
levels of clones #5 and #6 were similar to those in
BCV-infected cells (see Fig. 3A, c), we used these 2 cell
clones for all subsequent experiments.
Generation and characterization of pseudotyped
chimeric viruses
To explore the possibility that phenotypically chimeric
viruses can be generated by infecting a virus into cells
that stably express a heterologous viral envelope pro-
tein, we used MHV A59 to infect DBT cells that stably
express the BCV S protein (DBT/BS). We expected that
such infections would result in the generation of chi-
meric viruses the surface proteins of which would be a
mixture of the MHV S protein and the BCV S protein,
while its genome and other structural proteins would be
the same as MHV A59 (Fig. 2A). As a control, DBT cells
that stably express the vector alone (DBT/V) were in-
FIG. 1. Cloning, construction, and stable expression of the BCV S protein in DBT cells. (A) Schematic diagram for cloning and construction of the
BCV S gene. The names and relative locations of the three pairs of primers used for RT–PCR are indicated at the top of the figure. Only the S gene
ORF is shown. The resulting three RT–PCR fragments A, B, and X are also indicated. Critical restriction enzymes used for cloning and construction
are shown. S, complete BCV S gene. The CMV immediate early gene promoter (P) and neomycin resistance gene (neor) in pcDNA3 are indicated.
(B) Stable expression of the BCV S protein in DBT cells. DBT cells were transfected with pcDNA3/BS or pcDNA3 vector alone, and stable expressing
cells were selected with G418 (see Materials and Methods). Two cell clones that express the BCV S protein [(DBT/BS#5 (c, d), DBT/BS#6 (e, f)] and
a cell clone that expresses vector alone [(DBT/V (a, b)] were grown on chamber slides, fixed, and labeled with mAb (43C2) specific to BCV S and FITC
conjugates. Images of both fluorescence (a, c, e) and bright field (b, d, f) were taken using an inverted fluorescence microscope (Olympus IX70) with
an attached digital camera (Magnifier) at a magnification of 20. Images were saved as TIFF files and labeled in PowerPoint (version 5).
FIG. 2. Production of chimeric viruses. (A) Scheme of chimeric virus production. DBT cells stably expressing the BCV S protein (DBT/BS) or the
vector alone (DBT/V) were infected with MHV strain A59 at a m.o.i. of 10. Viruses were harvested when the cytopathic effect reached 90%. Chimeric
viruses that were produced from DBT/BS cells are termed A59/BS while those from DBT/V cells are designated A59/V. Unfilled circles represent the
BCV S protein; filled circles denote the MHV S protein. (B) Western blot analysis. All four viruses (indicated at the top of the gel) were purified through
sucrose gradients. Viral proteins were then separated by PAGE (10%) under nondenaturing condition (see details under Materials and Methods),
transferred to nitrocellulose membranes, and detected with mAb 43C2 specific to the BCV S protein and the ECL system. (C) Hemagglutination assay
showing the hemagglutination activity of the chimeric viruses. Viruses were purified through ultracentrifugation on a 30% sucrose cushion and then
on a 20 to 60% sucrose gradient. A twofold serial dilution of the virus preparation (indicated at top) was made in PBS in a V-shaped 96-well microplate.
An equal volume (50 l) of 0.5% mouse erythrocytes was added and incubated at 4°C for 2 h or overnight. HA titers were determined and images
were taken using a UVP Transluminator with visible light. A59/BS#5 and A59/BS#6 indicate two chimeric viruses generated from two separated cell
clones; BCV was a positive control, with a HA titer of 256 HA units.
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fected with MHV A59. The resulting progeny virus (A59/V)
would be genotypically and phenotypically the same as
MHV A59 (Fig. 2A). To establish that BCV S proteins are
indeed incorporated into the chimeric virions, virus prep-
arations were purified through sucrose gradients, sepa-
rated by SDS–PAGE under the nondenaturing conditions,
and analyzed by Western blotting using mAb 43C2 spe-
cific to the BCV S protein. As shown in Fig. 2B, the BCV
S protein was present in both chimeric virions (lanes 2
and 3), but not in A59/V (lane 1). The same S protein was
also detected in wild-type BCV (lane 4). We thus con-
clude that the BCV S protein was incorporated into the
chimeric virions.
To verify whether the incorporated BCV S protein re-
tained its biological function, we determined the hemag-
glutination activity of the chimeric viruses. It was re-
ported previously that the S protein purified from the BCV
virion possessed hemagglutinin activity when erythro-
cytes from several animal species were used in hemag-
glutination (HA) assay (Schultze et al., 1991). Moreover,
the BCV S protein is a stronger hemagglutinin that its HE
protein (Schultze et al., 1991). Indeed, both chimeric vi-
ruses, A59/BS#5 and A59/BS#6, which were generated
by infecting MHV A59 into DBT/BS#5 and DBT/BS#6
cells, respectively, exhibited hemagglutination activity (4
HA units, Fig. 2C). Because MHV A59 lacks the HE
protein and its S protein does not recognize the sialic
acid receptor on erythrocytes, MHV A59 would not ag-
glutinate erythrocytes. This was verified in A59/V (Fig.
2C). Therefore, the HA activity of the two chimeric viruses
must have been conferred from BCV S proteins that were
incorporated into the chimeric viruses during virus as-
sembly in DBT cells stably expressing the BCV S protein.
It is worth noting that the HA activity observed in the
chimeric virus was less likely conferred by free BCV S in
the virus preparations because the BCV S protein is
known to be a type I membrane protein and the virus
preparations were purified through a sucrose gradient
prior to HA assay. Samples prepared from mock-infected
DBT/BS#5 cells through the same sucrose gradient cen-
trifugation method did not contain the BCV S protein in
Western blot and did not exhibit HA activity (data not
shown, see Fig. 6 for an example). These results support
the conclusion that the chimeric viruses retained their
biological (receptor-binding) activity. However, the HA
titer of the chimeric viruses was lower than that of wild-
type BCV (256 HA units, Fig. 2C) even though an equiv-
alent number of virus particles [based on the radioactiv-
ity of the N proteins in a labeling experiment (data not
shown)] for all four viruses was used for the HA assay,
suggesting that the number or the binding activity of the
S protein or both in chimeric viruses are lower than those
of the S proteins in wild-type BCV virions. It should be
noted that the HA activity of the wild-type BCV is partially
contributed by the HE protein (see Fig. 6C).
The BCV S protein conferred the infectivity upon
chimeric MHV/BS virus
To determine whether the BCV S protein alone is
sufficient for initiation of viral infection, we used the
pseudotyped chimeric virus MHV/BS that contains the
BCV S protein on the virion surface (Fig. 2) to infect
HRT-18 cells. HRT-18 cells are permissive to BCV infec-
tion (Fig. 3A, c) and are widely used for BCV propagation,
but are not susceptible to MHV A59 infection (Fig. 3A, e).
Therefore, replication of the chimeric viruses in HRT-18
FIG. 3. Immunofluorescence detection of viral gene expression in
HRT-18 cells (A) and DBT (B). (A) Left column: HRT-18 cells were grown
on chamber slides and infected with BCV (c), A59/V (e), A59/BS#5 (g),
and A59/BS#6 (i) or were mock-infected (a). Cells were fixed and
labeled with mAb J3.3.1 specific for the MHV N protein (a, e, g, i) or with
mAb 43C2 specific for the BCV S protein (c) and FITC conjugates. Right
column (b, d, f, h, j): Respective viruses (indicated at left) were incu-
bated with a neutralizing mAb (43C2) prior to inoculation. (B) DBT cells
were grown on chamber slides and infected with A59/V with (c) or
without (b) prior treatment with mAb 43C2 or were mock-infected (a).
Cells were fixed and labeled with the MHV N-specific mAb J3.3.1 and
FITC conjugates. All images were taken using an inverted fluorescence
microscope (Olympus IX70) with an attached digital camera (Magnifier)
at a magnification of 20.
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cells would indicate a successful entry of the viruses,
which must be mediated solely by the BCV S protein. To
monitor the replication and gene expression of the chi-
meric viruses in cells, we used mAb J3.3.1 specific to
MHV N protein in IF assay. As expected, both chimeric
viruses replicated in HRT-18 cells at 24 h p.i., as demon-
strated by the expression of the MHV N protein (Fig. 3A,
g and i). These fluorescence stainings were specific
because neither the mock-infected nor the MHV A59-
infected HRT-18 cells were stained with the N protein
mAb and fluorescein isothiocyanate (FITC) conjugates
(Fig. 3A, panels a and e).
To ensure that entry of chimeric viruses was indeed
mediated by the BCV S protein, we used neutralizing
mAb 43C2 specific to the BCV S protein (Hussain et al.,
1991) in a virus-neutralizing assay. mAb 43C2 was mixed
with different virus preparations and incubated for 1 h at
37°C prior to inoculation into HRT-18 cells. At 24 h p.i. the
same IF assay was used for detecting viral gene expres-
sion using mAb J3.3.1 for MHV A59 and the chimeric
viruses and mAb 43C2 for BCV. As shown in Fig. 3A (d, h,
and j), prior incubation with neutralizing mAb 43C2 com-
pletely blocked the infection of HRT-18 cells by BCV and
the two chimeric viruses. However, this result did not
exclude the possibility that mAb 43C2 may also have
been able to neutralize MHV infectivity by cross-reacting
with the MHV S protein. To rule out this possibility, MHV
A59 was incubated with mAb 43C2 for 1 h at 37°C prior
to infection of DBT cells. Regardless of the incubation
with mAb 43C2, MHV A59 replicated equally well in DBT
cells, as evidenced by the cytopathic effect, cell fusion,
syncytium formation, and strong fluorescence staining
with the N mAb (Fig. 3B), indicating that mAb 43C2 did
not neutralize MHV infectivity. Taken together, these re-
sults clearly demonstrated that the BCV S protein but not
the other structural proteins of MHV origin conferred the
infectivity of the chimeric viruses in HRT-18 cells.
We assumed that the chimeric viruses so generated
should contain a mixture of two S proteins (MHV S and
BCV S), while the remaining structural proteins and the
genome should be identical to those of the wild-type
MHV A59. If the BCV S protein is used for chimeric virus
infection into HRT-18 cells, then BCV S protein should be
left outside the infecting cells during virus uncoating and
entry, and the progeny virus recovered from HRT-18 cells
should be identical to wild-type MHV A59 (Fig. 4A). To
test this hypothesis, medium was collected from cultures
of HRT-18 cells infected with the chimeric viruses, and
the recovered virus, designated passage I virus, was
used for infection of both DBT and HRT-18 cells. The IF
assay using the MHV N-specific mAb was performed to
detect viral gene expression in these cells. As shown in
Fig. 4B, both passage I viruses replicated in DBT cells (e
and f), but not in HRT-18 cells (b and c), supporting our
hypothesis. Furthermore, these results support our con-
clusion that entry of the chimeric viruses into HRT-18
cells is mediated solely by the BCV S protein.
Establishment of cell lines that stably express the
BCV HE protein
Having established the system for stably expressing
viral spike protein and for generating chimeric viruses,
FIG. 4. Inability in continuous passage of the chimeric viruses in
HRT-18 cells. (A) Schematic diagram for generating passage one (P1)
viruses. HRT-18 cells were infected with chimeric viruses (A59/BS). The
resulting virus, designated A59/BSP1, was used to infect HRT-18 and
DBT cells. (B) Fluorescence detection of P1 viral gene expression in
HRT-18 (a–c) and DBT (d–f) cells. Cells were grown on chamber slides
and infected with both P1 viruses or were mock-infected. At 24 h p.i. (for
HRT-18) or 9 h p.i. (DBT), cells were fixed and labeled with MHV
N-specific mAb J3.3.1 and FITC conjugates. Images were taken using
an inverted fluorescence microscope (Olympus IX70) with an attached
digital camera (Magnifier) at a magnification of 20.
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we sought to extend our investigation and to define the
role of the HE protein in BCV pathogenicity. For this
purpose, the HE protein of BCV virulent strain LY-138 was
expressed in DBT cells via the eukaryotic expression
vector pcDNA3, as described for the BCV S protein (Fig.
1A). A total of 50 individual cell clones that were resistant
to G418 treatment for approximately 4 weeks was ob-
tained. To identify the expression of the HE protein, we
used a rabbit polyclonal antibody specific to the 8 aa
Flag epitope that was fused to the carboxyl terminus of
the HE protein (see Materials and Methods) in an IF
assay. Of the 50 cell clones, 7 exhibited a low level of
expression, 19 a medium level, 19 a high level, and 5 the
highest level of expression. Figure 5A (c and e) shows 2
representative clones (DBT/BHE#5 and DBT/BHE#7) that
had the highest expression of the BCV HE protein as
judged by fluorescence intensity. The intracellular stain-
ing appeared to be specific, since it was not observed in
DBT/V cells that were stably transfected with the vector
alone (Fig. 5A, a). All cells expressed the HE protein, as
determined by comparing the fluorescence images with
their bright field images (compare c with d and e with f).
The intracellular localization and the abundance of the
HE protein varied from cell to cell, and the expressed
FIG. 5. Stable expression of the BCV HE protein in DBT cells. (A) DBT cells were transfected with pcDNA3/BHE or pcDNA3 vector alone and stable
expressing cells were selected with G418 (see Materials and Methods). Two cell clones that express the BCV HE protein [DBT/BHE#5 (c, d),
DBT/BHE#7 (e, f)] and a cell clone that expresses vector alone [DBT/V (a, b)] were grown on chamber slides, fixed, and labeled with polyclonal
antibody specific to the Flag and FITC conjugates. Images of both fluorescence (a, c, e) and bright field (b, d, f) were taken using an inverted
fluorescence microscope (Olympus IX70) with an attached digital camera (Magnifier) at a magnification of 20. (B) Acetylesterase activity of
DBT/BHE#5 and DBT/BHE#7 cell lines. The activity was determined by hydrolysis of p-nitrophylacetate (PNPA) using cellular protein from total cell
lysates. Five micrograms protein of each sample was incubated with 1 mM PNPA for various times at room temperature. Absorbency at 405 nm was
read every 2 min and values were recorded after the subtraction of PNPA values. Each sample was assayed in triplicate. The SigmaPlot graphics
program (IBM) was used to generate the graph.
228 POPOVA AND ZHANG
characteristics were similar to those of the S protein
(compare Fig. 5A with Fig. 1B).
Although the IF assay detected the expression of the
BCV HE protein, it could not determine whether the
expressed HE protein retains its biological activity. One
of the biological activities of the BCV HE protein is the
receptor-destroying function by its acetylesterase.
Therefore, DBT cells expressing the BCV HE protein
were lysed by repeated freezing and thawing. The pa-
rental DBT cells and DBT cells expressing vector alone
were used as negative controls. Cell lysates containing
equivalent amounts of protein (5 g) for each sample
were subjected to acetylesterase assay. As shown in Fig.
5B, both of the cell clones (DBT/BHE#5 and DBT/BHE#7)
that express the BCV HE protein had a significantly
higher esterase activity (fivefold higher OD values at 12
min) than those of the parental cells (DBT) or cells ex-
pressing vector alone (DBT/V), indicating that the ex-
pressed HE protein retained its biological function with
respect to the esterase activity.
Generation and characterization of MHV/BCV HE
chimeric viruses.
Since the biologically functional HE protein was stably
expressed, we proceeded to make chimeric viruses by
infecting these cells with MHV A59. MHV A59 was cho-
sen for this experiment because it does not contain the
HE protein. To ensure that the HE protein was indeed
incorporated into the chimeric virus particles, several
approaches were employed. First, we used radiolabeling
of chimeric viral proteins. Cells were infected with MHV
A59 and proteins radiolabeled with [35S]methoinine. Chi-
meric viruses were then purified through sucrose gradi-
ents, and viral structural proteins were separated by
SDS–PAGE. As shown in Fig. 6A, both representative
chimeric viruses contained the BCV HE protein (lanes 2
and 3). The amount of HE protein incorporated into the
chimeric virions was approximately 25% of the wild-type
BCV HE, when it was normalized by the N proteins (Fig.
6A, bottom, compare lanes 2 and 3 with lane 4). This
protein did not appear in A59/V (Fig. 6A, lane 1). These
results indicated that the BCV HE protein is likely incor-
porated into the chimeric virions. Second, we carried out
Western blot analysis on chimeric virion proteins. The
engineered BCV HE protein was detected in relatively
similar amounts in both sucrose-gradient purified chi-
meric virions by the anti-Flag antibody in Western blot
FIG. 6. Characterization of MHV/BCV HE chimeric viruses. (A) De-
tection of BCV HE/Flag in chimeric viruses. DBT cells stably expressing
the BCV HE protein or the vector alone were infected with MHV A59,
and HRT-18 cells were infected with BCV LY-138. Cells were then
labeled with [35S]methionine (100 Ci/ml). Viruses were collected from
the medium and purified through a sucrose gradient. Viral proteins
were separated by SDS–PAGE on a 10% gel and visualized by Phos-
phorImager (Molecular Dynamics). Lanes 1–3, as in the figure; lane 4,
BCV LY-138. The viral structural proteins are indicated by arrows at
right. The radioactivity of the N and HE bands was determined with the
PhosphorImager software (ImageQuant, version 4.2a, build 13, Molec-
ular Dynamics). The amount of HE protein in each virus was normalized
by its N protein based on radioactivity and is presented at the bottom
of the gel as a percentage relative to the HE protein in wild-type BCV.
M, molecular weight standards in kDa. (B) Detection of BCV HE/Flag in
chimeric viruses by Western blot analysis. Purified virions were sepa-
rated by SDS–PAGE on a 10% gel and were transferred to nitrocellulose
membrane. The viral proteins were labeled with antibody to Flag
followed by peroxidase (see Material and Methods). Lanes 1–3, as in
the figure. Lane 4, “virus” preparation from mock-infected DBT cells
expressing the BCV HE protein (DBT/BHE#5). The band representing
BCV HE/Flag is indicated by an arrow at right. (C) Hemagglutination
assay showing the hemagglutination activity of the A59/BHE chimeric
viruses. Viruses were purified through ultracentrifugation on a 30%
sucrose cushion and then on a 20 to 60% sucrose gradient. Twofold
serial dilutions (indicated at top) of the virus preparations (as indicated
at left) were made in a V-shaped 96-well microplate. An equivalent
number of virions for all viruses (based on the radioactivity of the N
protein shown in A) was used for the assay. An equal volume (50 l) of
0.5% mouse erythrocytes was added to each well and incubated at 4°C
for 2 h or overnight. HA titers were then determined and images were
taken using a UVP transluminator with visible light. A59/BHE#5 and
A59/BHE#7 indicate two chimeric viruses generated from two sepa-
rated cell clones; BCV, a positive control, with an HA titer of 512 units.
BCV (Ab), BCV was treated with mAb 43C2 for 1 h at 37°C prior to
incubation with erythrocytes.
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(Fig. 6B, lanes 2 and 3), but not in A59/V (lane 1), con-
firming that the BCV HE protein was present in the
chimeric virions. Since no HE protein was detected in the
sucrose-gradient preparation purified from mock-in-
fected, HE-expressing DBT/HE#5 cells (Fig. 6B, lane 4),
this further established that the HE protein detected in
the chimeric virus preparations (lanes 2 and 3) was truly
incorporated into the virion rather than a contaminant of
HE-containing cellular vesicles. Third, we used the hem-
agglutination assay to assess the receptor-binding ac-
tivity of the BCV HE protein in the chimeric viruses.
Indeed, both chimeric viruses A59/BHE#5 and A59/
BHE#7 possessed hemagglutination activity (2 HA units),
whereas control virus A59/V did not (Fig. 6C), demon-
strating that the HE protein of the chimeric virus retained
its receptor-binding activity. Finally, to provide a relatively
quantitative assessment, we performed a hemagglutina-
tion inhibition assay. Because both the S and HE proteins
of BCV agglutinate erythrocytes, the relative contribution
of each individual protein needs to be determined. We
used mAb 43C2 to block the hemagglutination activity
mediated by the S protein. As a result, the HA titer of BCV
was reduced from 512 to 16 units [Fig. 6C, compare row
BCV with BCV(Ab)], indicating that the remaining 16 HA
units are likely contributed by the HE protein. This esti-
mate is reasonable because the concentration of the
mAb was in greater excess to completely block S protein
binding (data not shown). If this estimate is correct, then
the HA titers of the chimeric viruses would be eightfold
less than that contributed by the HE in wild-type BCV
(Fig. 6C). An equivalent number of virus particles for each
virus preparation as estimated from radiolabeled N pro-
tein (Fig. 6A) was used for the HA and hemagglutination
inhibition (HI) assays. Thus, these data indicate that the
BCV HE protein was incorporated into the chimeric viri-
ons and retained its receptor-binding activity but that its
amount in the chimeric viruses was lower than that in
wild-type BCV. It is important to note, however, that the
relative receptor-binding activity of the HE protein in the
A59/BHE chimeras may be similar to that of the S protein
in the A59/BS chimeras compared with those in BCV,
since A59/BS had a twofold higher HA titer (4 HA units)
than A59/BHE (2 HA units) and the S protein had a
twofold higher HA titer (32 HA units) than the HE protein
(16 HA units) in BCV (compare Fig. 6C with Fig. 2C).
The BCV HE protein alone is not sufficient for
chimeric virus infection in HRT-18 cells
To define the role of the HE protein in BCV pathoge-
nicity, two chimeric viruses (A59/BHE#5 and A59/BHE#7)
were used to infect HRT-18 cells, which are permissive to
BCV infection but not to MHV infection. The mAb specific
to the MHV N protein was used in an IF assay to monitor
the gene expression of the chimeric viruses. As shown in
Fig. 7, none of the HRT-18 cells infected with the chimeric
viruses exhibited any fluorescence, nor did those in-
fected with A59/V or the mock-infected cells (Fig. 7, a–d),
indicating that the chimeric viruses could not infect
HRT-18 cells. To rule out the possibility that the chimeric
viruses lost infectivity during virus preparation, DBT cells
were also infected with these viruses. The result showed
that both chimeric viruses were viable at the time of
infection (Fig. 7, g and h). These results indicate that the
BCV HE protein on chimeric virions was unable to facil-
itate chimeric virus infection in HRT-18 cells, suggesting
that the HE protein alone was not sufficient for BCV
infection.
DISCUSSION
In this study, we developed a system in which a viral
surface protein (spike or hemagglutinin/esterase) of a
FIG. 7. Chimeric virus that contained MHV S and BCV HE on the viral
surface failed to infect HRT-18 cells. Cells were grown on chamber
slides and were infected with two chimeric viruses, A59/BHE#5 (d, h)
and A59/BHE#7 (c, g), or the control virus A59/V (b, f) or were mock-
infected (a, e). At 24 h p.i. (HRT-18, a–d) or 9 h p.i. (DBT, e–h), cells were
fixed and labeled with MHV N-specific mAb J3.3.1 and FITC conjugates.
Images were taken using an inverted fluorescence microscope (Olym-
pus IX70) with an attached digital camera (Magnifier) at a magnification
of 20.
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closely related BCV was stably expressed in MHV-per-
missive cells and chimeric viruses were generated by
infecting MHV in these stably expressing cells. The chi-
meric virus contains the genome of wild-type MHV, but
the proteins present on the virion surface are a mixture of
two types of proteins derived from MHV and BCV. Such a
virus is pseudotyped, i.e., only phenotypically chimeric.
Using this system, we generated two types of chimeric
viruses: one containing a mixture of the MHV S and BCV
S proteins (A59/BS) and the other containing a mixture of
the MHV S and BCV HE proteins (A59/BHE) on the virion
surface. Because the chimeric virus contains a single
BCV envelope protein, the role of the individual protein in
BCV cytopathogenicity can be unequivocally determined
by infecting the chimeric virus (A59/BS or A59/BHE) into
cells (i.e., HRT-18) that are nonpermissive to MHV infec-
tion but that are susceptible to BCV infection. If the
chimeric virus were to enter the HRT-18 cells and repli-
cate, this would indicate that the BCV envelope protein
confers infectivity upon the chimeric virus. Our rationale
for developing such a system is based on the fact that
the surface glycoproteins (S and HE) of MHV and BCV
recognize distinct classes of receptors on the cell sur-
face and thus have different cell-type specificity. We also
took advantage of the availability of two different cell
lines that are permissive to infection by only one type of
virus (MHV or BCV). The phenotypically chimeric viruses
thus allow us to address questions of BCV–cell interac-
tions in the current study.
To date, the question of whether the S protein alone is
sufficient for BCV infection has remained unanswered.
Our present results clearly demonstrated that the chi-
meric MHV/BCV S entered and replicated in HRT-18
cells, which are nonpermissive to infection by the paren-
tal MHV (Fig. 3). Infection of HRT-18 cells by the chimeric
virus was completely blocked by prior treatment of the
virus with mAb 43C2, which is specific to the BCV S
protein, but the infection of DBT cells by the chimeric
virus was not inhibited by the same mAb treatment (Fig.
3). This supports the conclusion that entry of the chi-
meric virus to HRT-18 cells is mediated specifically and
solely by the BCV S protein present on the surface of the
chimeric virus. Our data provide an unequivocal answer
that the S protein is necessary and sufficient for BCV
infection. These findings thus suggest that, regardless of
the presence of the HE protein, all coronaviruses likely
use the S protein as the primary vehicle for infection in
permissive cells.
The precise role of the HE protein in BCV infection has
also remained unclear. We addressed this issue by in-
fecting HRT-18 cells with the chimeric MHV containing
the BCV HE protein on the virion surface. We found that
the chimeric virus (A59/BHE) could not enter into HRT-18
cells (Fig. 7) despite the fact that the HE protein of the
chimeric virus retains its receptor-binding (hemaggluti-
nation) and receptor-destroying (acetylesterase) activi-
ties (Fig. 6C and data not shown). Our results thus
suggest that the HE protein alone is not sufficient for
BCV infection. Alternatively, it is possible that the low
incorporation of the HE protein into chimeric MHV/BHE
(Fig. 6) may contribute to the inability of the chimera to
enter HRT-18 cells. However, the finding that chimeric
MHV/BS is sufficient for viral infection (Fig. 3) further
suggests that the HE protein is not necessary for BCV
infection. This is similar to MHV, in which the HE protein
is found to be dispensable (Gagneten et al., 1995), thus
negating the hypothesis that the HE protein is required
for BCV infectivity. However, our results do not exclude
the possibility that the HE protein may play other roles in
BCV entry. The demonstration of the receptor-binding
(hemagglutination) and esterase activities of the BCV HE
protein clearly supports the notion that the HE protein
plays a role in BCV pathogenicity. This may be achieved
by its ability to bind to sialic acid-containing receptors
and to facilitate the release of bound virus from the
receptors on the cell surface. That the hemagglutination
of BCV was partially contributed by the HE protein (Fig. 6
in this study; Schultze et al., 1991) further supports such
an assumption. Whether and to what extent the HE
protein contributes to BCV infection in cell culture and in
animals remains to be investigated further.
We have also tested indirectly the hypothesis that both
the S and HE proteins of BCV bind to the same receptor
on permissive cells. We found that when HRT-18 cells
were incubated with the HE protein from lysates of HE-
expressing DBT cells prior to infection, the infectivity of
both MHV/BCV S chimeras (A59/BS#5 and A59/BS#6)
was inhibited, which correlated with increased amounts
of the HE protein (data not shown). This suggested that
either the HE protein competed with the S protein for the
same receptor on HRT-18 cells or the receptors were
destroyed by the acetylesterase of the HE protein. Sim-
ilar results were obtained with the HA assay (data not
shown). In all cases, the data are consistent with previ-
ous findings that both S and HE of BCV recognized the
same receptor on cultured cells and erythrocytes (Schul-
tze et al., 1991; Schultze and Herrler, 1992, 1994).
Our conclusion that the S protein but not the HE
protein of BCV is necessary and sufficient for BCV infec-
tion in permissive cells is consistent with the biology of
viral infection in general and coronavirus structural pro-
teins in particular. For almost all enveloped viruses, entry
into cells requires two major steps: attachment of viral
envelope proteins to receptors on host cells and fusion
between viral envelope and cytoplasma or endosomal
membranes. The S protein of all coronaviruses pos-
sesses both such functions, while the HE protein of BCV
has the receptor-attachment function but lacks the fusion
activity. This is in contrast to the HEF protein of influenza
C virus, which possesses the receptor-binding, esterase,
and fusion activities (Herrler et al., 1985, 1988). The lack
of the fusion activity in the BCV HE protein may indicate
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that the HE protein alone is insufficient for BCV infection.
Our data contradict the conclusions by Deregt and
Babiuk (1987) drawn from experiments on monoclonal
antibody to the HE protein. One possible interpretation of
this discrepancy is that the HE-specific mAbs they used
may have interfered with the binding of the S protein to
the receptor by steric hindrance or by other undefined
mechanisms. Experiments are currently underway to test
whether a chimeric virus containing both the BCV S and
HE proteins has increased infectivity in HRT-18 cells
compared to a virus expressing BCV S alone. These
experiments will likely identify auxiliary roles of the HE
protein, if any, in BCV infection.
The issue of how the BCV S and HE proteins were
incorporated into the chimeric viruses was not ad-
dressed in this study. Godeke et al. (2000) showed that
interaction between the C-terminal cytoplasmic domains
of the S protein and the M protein is essential for the S
protein to be incorporated into the virion. Sequence com-
parison of the cytoplasmic tail of the S proteins showed
a high degree of amino acid identity between MHV and
BCV (data not shown). This suggests that the cytoplas-
mic tail of the BCV S protein might have interacted with
the MHV M protein during virus assembly. Such chime-
ras are common, especially between related viruses,
such as those between feline coronavirus and MHV (Kuo
et al., 2000). However, nothing is known about HE se-
quences in virion assembly. Apparently, the expression
of the 8-aa Flag epitope at the carboxyl terminus did not
block its incorporation, since the Flag-containing HE
protein was clearly detected in the chimera (Fig. 6),
although its effect on the efficiency of incorporation has
not been determined.
MATERIALS AND METHODS
Virus, cells, and antibodies
MHV strain A59 was used throughout this study. For
some experiments, MHV strain JHM and BCV virulent
strain LY-138 (Zhang et al., 1991a,b) were also used. The
murine astrocytoma cell line (DBT) (Hirano et al., 1974)
was used for propagation of MHV, expression of recom-
binant proteins, production of chimeric virus, and other
experiments involving MHV infection. DBT cells were
grown in 1Minimum Essential Medium (MEM) contain-
ing 7.5% newborn calf serum (GIBCO BRL). The G clone
of human rectal tumor (HRT-18) cells [kindly provided by
J. Storz, Louisiana State University (LSU), Baton Rouge,
LA] was used for experiments involving BCV infection.
HRT-18 cells were grown in Dulbecco’s modification of
Eagle’s medium (DMEM) containing 10% fetal bovine
serum.
Monoclonal antibody J3.3.1 specific to the MHV N
protein and mAb 43C2 specific to the BCV S protein were
kindly provided by Drs. S. A. Stohlman (University of
Southern California, Los Angeles, CA) and J. Storz, LSU,
respectively. mAb 43C2 contains neutralizing activities to
BCV and it only recognizes the conformational epitope
(Hussain et al., 1991). The rabbit polyclonal antibody
specific to the 8-aa Flag epitope was purchased from
Neomarkers (San Diego, CA).
Plasmid construction
For expressing the BCV S protein in mammalian cells,
the full-length BCV S gene was cloned into eukaryotic
expression vector pcDNA3 (Promega) under the control
of an immediate early gene promoter of CMV. Briefly,
HRT-18 cells were grown to monolayers and were in-
fected with BCV virulent strain LY-138 at a multiplicity of
infection (m.o.i.) of 10 in the presence of actinomycin D
(10 g/ml). At 24 h postinfection, cells were lysed and
total intracellular RNAs were isolated with the Trizol RNA
isolation reagent (GIBCO BRL). RNAs were subjected to
reverse transcription (RT) reaction with antisense prim-
ers 3BCVS2200Eco [5-TTT GAA TTC AGG TTG CAG
CTG TCG TGA AAG A-3, complementary to the se-
quence of the BCV S gene open reading frame (ORF) at
nucleotide (nt) positions 2178–2200] and 3BCVSBam
(5-AAC GGA TCC AAT ATA TCG TCA GGA GCC AAT
A-3, complementary to the sequence of the BCV S gene
at the last 22 nt). The restriction enzyme sites incorpo-
rated into the primer sequences are underlined through-
out this section. cDNAs were then amplified by PCR with
sense primers 5BCVS2187Eco (5-GCT GAA TTC TCT
TTC ACG ACA GCT GCA ACC T-3, corresponding to nt
2187–2209 of the BCV S gene) and 5BCVSEco (5-GCT
GAA TTC GAT AAT GGT ACT AGG CTG CAT GAT-3,
corresponding to the sequence at the 5-end of the BCV
S gene) (see Fig. 1A). RT–PCR was performed as de-
scribed previously (Zhang et al., 1991b). PCR fragment A,
which contains the 5-end 2.2 kb of the S gene, was
digested with EcoRI and cloned into the EcoRI site of
pUC19 (GIBCO BRL), resulting in pUC/A; fragment B,
which contains the 3-end 2.0 kb of the S gene, was
digested with EcoRI and BamHI and cloned into the
EcoRI-BamHI sites of pUC19, resulting in pUC/B. Frag-
ment A was then subcloned into the EcoRI site of pUC/B,
resulting in pUC/AB. The orientation of fragment A in
pUC/AB was verified by internal restriction enzyme di-
gestions. pUC/AB was then digested with BstXI and
TthIII I, and the smaller BstXI-TthIII I fragment was re-
placed by an additional fragment X, which was made in
RT–PCR with primers 5BCVS983 (5-TTG CAG ATG TTT
ACC GAC GTA TAC-3, corresponding to nt 983–1007 of
the BCV S gene) and 3BCVS2380 (5-CAG TAA ATG GCT
CAA AAT TAG T-3, complementary to nt 2358–2380 of
the BCV S gene), generating pUC/BCVS (the full-length
4.2 kb S gene in pUC19). Sequences of fragments A, B,
and X were determined and published previously (Zhang
et al., 1991b). For subcloning into the pcDNA3 expression
vector, the 3-end BamHI site was converted into an
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EcoRI site by digestion of pUC/BCVS with BamHI, blunt-
ending with T4 DNA polymerase, dephosphorylation with
calf intestinal phosphatase (CIP), and ligation with T4
DNA ligase with an EcoRI linker. The resulting plasmid
pUC/BCVSee contains an EcoRI site at both ends. pUC/
BCVSee was digested with EcoRI and cloned into the
EcoRI site of pcDNA3 vector, resulting in pcDNA3/BS.
The orientation of the insert was confirmed by restriction
enzyme digestions.
For constructing plasmid containing the BCV HE gene,
all procedures were similar to those used for the BCV S
gene except for the following steps. cDNA fragments
containing the entire BCV HE gene were synthesized
from viral RNA by RT–PCR with primers 3BCVHE/Flag
[5-TTT GAA TTC TTA CTT GTC ATC GTC GTC CTT GTA
GTC AGC ATC ATG CAG CCT-3, containing a sequence
complementary to the last 15 nt of the BCV HE gene, the
coding sequence for the 8-aa Flag epitope (Asp Tyr Lys
Asp Asp Asp Asp Lys), the stop codon, and an EcoRI site]
and 5SpeIG/BCV HE (5-TAA CTA GTG AAT CTA ATC
TAA ACT TTA AGG AAT GTT TTT GCT TCC-3, containing
an SpeI site, an MHV intergenic consensus sequence,
and the first 15 nt of the BCV HE gene). RT–PCR products
were gel purified, digested with SpeI and EcoRI, and
cloned into the SpeI-EcoRI site of previously constructed
MHV defective-interfering RNA vector pDE25CAT (Liao
and Lai, 1994), resulting in pDE/BCV-HE. For stably ex-
pressing the BCV HE protein, pDE/BCV-HE was digested
with SpeI, blunt-ended with T4 DNA polymerase, and
then digested with EcoRI. The SpeI (blunt-ended) EcoRI
fragment of the BCV HE gene was cloned into the HindIII
(blunt-ended) EcoRI sites of the pcDNA3 vector, resulting
in pcDNA3/BHE.
DNA transfection and selection of stable
transfectants
DBT cells were grown in MEM in 60-mm culture plates
(Sarsted) to 60–70% confluence and were transfected
with plasmid DNAs containing the pcDNA3 vector alone
or vectors with the BCV S gene (pcDNA3/BS) or the HE
gene (pcDNA3/BHE) by use of the cationic liposome
transfection reagent DOTAP according to the manufac-
turer’s instructions (Boehringer Mannheim). Briefly, 7 g
of each construct was mixed with 14 g of DOTAP in 65
l of 20 mM HEPES (pH 7.4). The mixture was then
added to DBT cells. Following incubation for 4 h, gene-
ticin (G418) (GIBCO BRL) was added to the medium at the
final concentration of 800 g/ml, and cells were grown
for 2 to 3 days. Cells that died off during this period were
removed, while surviving cells were allowed to grow
further in the presence of G418. Individual cells were
cloned into 96-well culture plates and were selected by
G418. Individual clones that were resistant to G418 treat-
ment for 3–5 weeks were screened for expression of the
S or HE protein of BCV.
Immunofluorescence assay
Indirect immunofluorescence assay was performed for
detection of recombinant gene expression or viral repli-
cation according to protocol described previously (Wang
and Zhang, 1999). Briefly, cells were grown to subconflu-
ence on 8-well chamber slides (Lab Tak, Nunc, and
Nalgene), fixed with 2% formaldehyde in phosphate-buff-
ered saline (PBS) for 30 min at room temperature, and
permeabilized with acetone for 15 min at 20°C. Cells
were washed three times with PBS containing 5% horse
serum, air dried, and incubated with a primary antibody
(mAb 43C2 for the BCV S protein or polyclonal Ab anti-
Flag for BCV HE). For detection of viral replication, mAb
J3.3.1 and mAb 43C2 were used for MHV and BCV,
respectively. Cells were then washed three times with
PBS containing 5% horse serum and stained with an
appropriate secondary antibody conjugated with FITC at
a 1:1000 dilution for 2 h at 37°C. After a washing with
PBS containing 5% horse serum, slides were mounted
and observed under an inverted fluorescence micro-
scope (Olympus IX70, filter BA515IF nm). All images were
taken using a digital camera (Magnifier) with a magnifi-
cation of 20.
Generation of pseudotyped chimeric viruses
Individual cell clones that stably express the BCV S or
HE protein were grown to confluence. Cells that were
stably transfected with the vector alone were also grown
to confluence and used as a control. These cells were
then infected with MHV A59 at a m.o.i. of 10. When
complete fusion of the monolayer appeared, culture me-
dium was taken and clarified from cell debris by centrif-
ugation at 8000 rpm for 30 min in a benchtop centrifuge
(Marathon 3200R, Fisher Scientific). Clear supernatants
were used as chimeric virus preparations.
Radiolabeling and analysis of virion proteins
Cell lines were infected with MHV A59 or BCV LY-138
at a m.o.i. of 10. At 2 h p.i. medium was replaced with
methionine-free MEM (for DBT cells) or DMEM (for
HRT-18 cells) and cells were incubated for an additional
2 h. Medium was then removed and replaced with fresh
methionine-free MEM or DMEM containing [35S]methi-
onine at 100 Ci/ml (800 Ci/mmol, Amersham). Virus was
harvested from the medium when the cytopathic effect
reached approximately 80–90% of the cells. Medium was
purified from cell debris by centrifugation at 8000 rpm
(Marathon 3200R) for 30 min. For virus purification, vi-
ruses were pelleted over a 30% (w/v) sucrose cushion by
centrifugation at 27,000 rpm in an SW40.Ti rotor (Beck-
man) for 3.5 h at 4°C. The pellets were resuspended in 1
ml of PBS and subjected to a sucrose step gradient [(20,
30, 40, 50, and 60% (w/v)] centrifugation at 35,000 rpm in
an SW40.Ti rotor for 16 h at 4°C. After centrifugation, the
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gradients were fractionated at 1 ml per fraction. The
radioactivity of each fraction was determined in a liquid
scintillation counter (Beckman LS6000TA). Fractions that
contained high radioactivity counts (usually between 40
and 50% sucrose) were combined and pelleted by cen-
trifugation at 35,000 rpm for 1 h in an SW40.Ti rotor.
Nonradiolabeled viruses were purified using the same
procedure as for radiolabeled viruses. Pelleted virus was
resuspended in 50 l of Lammeli’s protein electrophore-
sis sample buffer. Equivalent counts for each sample
were loaded and proteins were separated by sodium
dodecyl sulfate–polyacrylamide gel (10%) electrophore-
sis (SDS–PAGE). To quantify viral proteins, the gel was
exposed to a PhosphorImager screen and analyzed by a
PhosphorImager (445SI Molecular Dynamics, Sunnyvale,
CA). The amount of radioactivity in each band was de-
termined with the software program ImageQuaNT (ver-
sion 4.2a, build 13).
Western blot analysis
For Western blot analysis, purified virus was resus-
pended in PBS and the concentration of viral proteins
was determined with the Bio-Rad protein assay kit. Un-
der denaturing conditions, 10 g of protein for each
sample was resuspended in 20 l of Lammeli’s electro-
phoresis sample buffer, boiled for 3 min, and resolved by
SDS–PAGE on a 10% gel. Under nondenaturing condi-
tions, proteins were resuspended in a buffer containing
0.1% SDS without dithiothreitol; the samples were not
boiled prior to loading, and proteins were separated by
SDS (0.1%)–PAGE as described previously (Zhang et al.,
1994). Proteins were then transferred to nitrocellulose
membrane (MSI, Westborough, MA) for 2 h at 100 V in a
transfer buffer (25 mM Tris, 200 mM glycine, 20% meth-
anol, 0.02% SDS). After being blocked with 5% skim milk
in PBS for 2 h at room temperature, a nitrocellulose
membrane was washed three times in Tris-buffered sa-
line containing 0.5% Tween 20 and immunoblotted with
Ab specific to Flag (5 g/ml) for 2 h at room temperature,
followed by a secondary Ab coupled to horseradish per-
oxidase (1:1000 dilution) (Sigma) for 1 h at room temper-
ature. The presence of the BCV HE protein was detected
by enhanced chemiluminescence (ECL) using peracid as
a substrate (Amersham) followed by autoradiography
with exposure times ranging from 30 s to 1 min.
Hemagglutination assay
The hemagglutination assay was performed as de-
scribed previously (Herrler et al., 1988). Briefly, mouse
erythrocytes were collected from BALB/c mice. A 0.5%
(v/v) erythrocyte suspension prepared in PBS was used
for the HA assay. A twofold serial dilution of virus sam-
ples in PBS was made in a V-shaped 96-well microtiter
plate (Falcon). An equal volume of the erythrocyte sus-
pension was added to each well, mixed, and incubated
at room temperature for 1–2 h. The HA titer was then
determined based on the reciprocal value of the maxi-
mum dilution that caused complete agglutination of
erythrocytes.
Hemagglutination inhibition assay
A modified hemagglutination inhibition assay was per-
formed. Briefly, 98 l of BCV preparations was mixed
with 2 l of mAb 43C2. Following incubation at 37°C for
1 h, the virus–antibody mixture was serially diluted two-
fold with PBS, and an equal volume (50 l) of erythrocyte
suspension was added to determine the HA titer.
Virus neutralization assay
Several dilutions (1:40, 1:80, 1:160, and 1:320) of mAb
43C2, which is specific to BCV S, were made in PBS and
incubated with 200 plaque-forming units of BCV LY-138,
MHV A59, or the chimeric viruses for 1 h at 37°C. The
antibody–virus mixtures were inoculated onto appropri-
ate cells as indicated. Replication of the virus was mon-
itored by immunofluorescence staining with mAb J3.3.1
for MHV A59 and mAb 43C2 for BCV. Alternatively, rep-
lication of the viruses was determined by viral plaque
assay (Spaan et al., 1981).
Acetylesterase assay
The acetylesterase assay was carried out as de-
scribed previously (Storz et al., 1992; Vlasak et al., 1988).
Briefly, cells were grown to confluence, scraped from the
plate using cell scrapers in 500 l of PBS, and washed
three times with PBS. For extraction of cellular proteins,
cells were frozen and thawed three times and centri-
fuged at 14,000 rpm in a microcentrifuge (IEC) for 5 min
at 4°C. The supernatants were transferred to new micro-
centrifuge tubes. The protein concentration of cell ly-
sates was determined with the Bio-Rad protein assay kit.
Five micrograms protein of each sample was incubated
with 1 ml of PBS containing 1 mM p-nitrophenol (Sigma)
as a substrate. The absorbency of each sample was
determined at a 2-min interval in a spectrophotometer
(U-2001) at 405 nm. Each sample was determined in
triplicate for each time point and the absorbency values
were plotted using SigmaPlot software (version 5.0, IBM).
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